Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.72 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.72 |
| ▸ | TNKS | O95271 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.72 |
| ▸ | POLA1 | P09884 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.72 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.72 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.72 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.72 |
| ▸ | PARP9 | Q8IXQ6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481738 | 1.00 | PARP1 (0.72) | PARP1DYRK3TNKSPGRCDK1 | |
| Phosphoric Acid SCHEMBL21122083 | 0.95 | PARP1 (0.74) | PARP1DYRK3TNKSPGRCDK1 | |
| SCHEMBL5003154 | 0.89 | PARP1 (0.74) | PARP1DYRK3TNKSPGRCDK1 | |
| SCHEMBL5002773 | 0.85 | PARP1 (0.75) | PARP1 | |
| SCHEMBL27015319 | 0.84 | PARP1 (0.79) | PARP1 | |
| SCHEMBL27293629 | 0.84 | PARP1 (0.79) | PARP1DYRK3TNKSPGRCDK1 | |
| SCHEMBL5005844 | 0.84 | PARP1 (1.00) | PARP1PARP2 | |
| Rucaparib SCHEMBL29351768 | 0.84 | PARP1 (1.00) | PARP1DYRK3TNKSPGRCDK1 | |
| Rucaparib SCHEMBL844585 | 0.84 | PARP1 (1.00) | PARP1DYRK3TNKSPGRCDK1 | |
| SCHEMBL5001991 | 0.83 | PARP1 (0.95) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023147400-A1 | COMPOSITIONS AND METHODS FOR INHIBITING STAG1 EXPRESSION AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023284262-A1 | 3,4-FUSED SEVEN-MEMBERED HETEROCYCLIC OXINDOLE, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF | 青岛农业大学 | 2023-01-19 | — | — | WO | disclosed |
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11021483-B2 | Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib | FORMOSA LABORATORIES, INC. (TW) | 2021-06-01 | — | — | US | disclosed |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | THE JACKSON LABORATORY (US) | 2021-02-23 | — | — | US | disclosed |
| CN-111989137-A | Compounds, compositions and methods for treating diseases involving acidic or hypoxic diseased tissue | 赛博克萨1公司 | 2020-11-24 | — | — | CN | disclosed |
| US-7429578-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| US-6977298-B2 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | Agouron Pharmacetucals, Inc. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | AGOURON PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1140936-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | WEBBER STEPHEN EVAN (US) | 2003-04-24 | — | — | US | disclosed |
| US-6495541-B1 | POTENTIATION OF ANTICANCER THERAPIES AND INHIBITION OF NEUROTOXICITY CONSEQUENT TO STROKE, HEAD TRAUMA, AND NEURO-DEGENERATIVE DISEASES; SUCH AS 2-BROMO-3,4-DIHYDROPYRROLO-(4,3,2-DE)ISOGUINOLIN-5-ONE | AGOURON PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1140936-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042040-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009517-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | PARP1 1/4885DYRK3 4009/4885TNKS 15/4885 |
| US-20050085460-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP2, PARP11 | PARP1 1/4885DYRK3 4009/4885TNKS 15/4885 |
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | OGG1, MGMT, TDP1 | PARP1 36/4885DYRK3 4370/4885TNKS 318/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PARP1 2/4885DYRK3 4226/4885TNKS 40/4885 |
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | PARP1 1881/4885DYRK3 4857/4885TNKS 2415/4885 |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885DYRK3 4249/4885TNKS 81/4885 |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP11, PARP2 | PARP1 1/4885DYRK3 4237/4885TNKS 15/4885 |
| US-11021483-B2 | Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib | GRHPR, HRAS, CHEK1 | PARP1 5/4885DYRK3 3360/4885TNKS 247/4885 |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, VHL | PARP1 1881/4885DYRK3 4857/4885TNKS 2415/4885 |
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, EGLN3 | PARP1 2085/4885DYRK3 4794/4885TNKS 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.